From GlobeNewswire: 2025-05-12 16:11:00

Enrollment is ongoing in the Phase 3 C-BEYOND trial for the treatment of HCV. Atea Pharmaceuticals presented full Phase 2 results for the regimen of bemnifosbuvir and ruzasvir at the EASL Congress 2025. A virtual investor event with key opinion leaders on HCV will be held on May 14, 2025, at 10:00 AM ET. The company reported financial results for the first quarter ended March 31, 2025, and provided a business update. The combination regimen of bemnifosbuvir and ruzasvir is in Phase 3 development for the treatment of HCV, with promising results from Phase 2 studies supporting its efficacy and safety. The regimen is expected to disrupt the global HCV market.

Results presented at EASL showed that the combination regimen of BEM and RZR for HCV achieved SVR12 in 98% of treatment-adherent patients. The regimen was safe and well-tolerated with low rates of virologic failure. Studies also showed no clinically significant drug-drug interactions, making it a potential best-in-class treatment option. The Phase 3 program includes trials in the US, Canada, and globally, comparing the regimen to a standard treatment.

Atea Pharmaceuticals has engaged Evercore to enhance shareholder value and reduce costs through workforce reduction. The company’s financial results for the first quarter of 2025 showed a decrease in research and development and general administrative expenses. Atea plans to continue developing antiviral therapies for serious viral infections, with a focus on HCV treatment. The company’s ongoing Phase 3 trials aim to address the unmet medical needs of patients with HCV.



Read more at GlobeNewswire:: Atea Pharmaceuticals Reports First Quarter 2025 Financial